ViroGates (VIRO.CO) Stock Analysis & AI Equity Report
ViroGates (VIRO.CO) overview
ViroGates (VIRO.CO) stock analysis and AI equity research. For the latest completed financial year, 2025, ViroGates reported revenue of DKK 5.3m and operating profit of DKK -14.1m; the year-end share price was 13.45 DKK and market capitalisation was DKK 106m. ViroGates is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ViroGates's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-06. Data will be refreshed during report generation.
About ViroGates
ViroGates A/S is a Danish medical diagnostics company that develops and commercializes suPARnostic®, a product line for measuring the suPAR biomarker in blood samples. Its tests include point-of-care, automated laboratory, and ELISA formats, used to support clinical triage, research, and assessment of inflammation and disease severity.
Generate the ViroGates report
ViroGates is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for ViroGates and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.